Scopolamine transmucosal - Anesta

Drug Profile

Scopolamine transmucosal - Anesta

Alternative Names: Oral transmucosal system - scopolamine; OTS - scopolamine; Scopolamine oral transmucosal system

Latest Information Update: 23 Aug 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anesta Corporation
  • Class Antiemetics; Antispasmodics; Hypnosedatives; Mydriatics; Tropanes
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Nausea and vomiting

Most Recent Events

  • 23 Aug 2006 Discontinued - Phase-I for Emesis in USA (Transmucosal)
  • 01 Nov 2000 Anesta has been acquired by Cephalon
  • 24 Jul 2000 Phase-I clinical trials for Emesis in USA (Transmucosal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top